Business Wire

Cirium Names December as Busiest Month for Air Travel Globally in 2021; Over 59,000 Flights Are Canceled Near Year-End, the Most in a Decade

Share

Aviation analytics firm Cirium, reveals that December was the busiest month in 2021 for flights globally, totaling 2.43 million, however the total number of flights canceled globally between December 24, 2021, and January 3, 2022, was 59,240, some 2.4%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105006010/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

According to Cirium data, the big four US airlines canceled nearly 7,040 flights between December 24 and January 3, 2022. Globally, over 59,000 flights were canceled over this period. (Graphic: Business Wire)

The number of cancelations over this period is the most cancelations in December for the past decade, six times more than the cancelations in 2019 and two and half times more than 2020. A total of 20,500 flights were canceled in the first three days of the new year.

The big four US airlines, including American Airlines, Delta Air Lines, Southwest Airlines and United Airlines, canceled nearly 7,040 flights over this period.

The cancelations being driven by the surging cases of the Omicron variant of COVID-19 and other operational challenges (including winter weather). Airlines rapidly canceled flights due to staff shortages across crew and ground operations.

Pre-Omicron, global flights flown increased 1.5% week-over-week (December 11-17, 2021). However, global flights are now down 5% compared to the week prior, following the impact of Omicron.

There are large variances between the regions, with the US, Europe and North Atlantic down 9-10%, China up 6%, while Asia-Pacific and Middle East are flat.

“Flight disruptions affect airlines and airports differently – it depends on the availability and flexibility of equipment and resources in place to react quickly. Those that plan more conservatively will minimize their operational disruptions. Cirium monitors the level of disruption by measuring completion factor of flights and their on-time performance,” said Jeremy Bowen CEO at Cirium.

“Cirium’s recent On-Time Performance Review shows how some airlines have focused on their operations to reduce the impact on passengers. For example, Delta Air Lines completed 99.8% of their flights from June to December 2021 and All Nippon Airways, the winner of the Global airline category in Cirium’s Review had a completion factor of 99.2%.”

Consideration is given to the carriers with high volumes of flights. For example, American Airlines flew the most flights in 2021 – around 1,850,050 – and still, its flights arrived 80.47% on time. The carrier did have trouble reinstating flight volumes after more than a year of deeply depressed demand yet completed 97.5% of its flights.

Hartsfield-Jackson Atlanta International Airport (ATL), the major hub for Delta Air Lines, was the busiest airport based on departing flights with 336,890 this year. Despite handling the most flights, it ranked 15th in on-time performance of the Top 20 Global airports.

Amsterdam Airport (AMS) was the busiest airport for international flights in 2021, with a total of 123,070 departing flights, however, it didn’t make the Top 20 airport rankings for on-time performance. Airports have experienced many variables this year in deploying comprehensive pandemic protocols, optimizing the reconciliation and collection of fees and services, and optimizing staffing.

Cirium’s On-Time Performance Review is the industry standard for airlines and airports operational performance. Cirium resumed reporting in June 2021, as flight volumes returned, with regular monthly updates that help gauge the industry’s performance in getting passengers from point A to point B, on time. Cirium’s on-time performance analysis is based on flight data from over 600 sources of real-time flight information.

Click here to download the complimentary On-Time Performance Review 2021.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insights, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cirium media team (Rachel Humphries/June Lee) at media@cirium.com
Juliett Alpha (Mike Arnot) at cirium@juliettalpha.com
The PC Agency (Paul Charles/Michael Johnson/Callum McGoldrick at cirium@pc.agency

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

HiddenA line styled icon from Orion Icon Library.Eye